Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jan 14, 2019
Eisai Inc. announced today the presentation of four abstracts at the 2019 Gastrointestinal Cancers Symposium (#GI19), taking place in San Francisco from January 17-19, 2019. The presentations...
Nov 28, 2018Project Unveils Powerful Portraits of People Living with Metastatic Breast Cancer and Their Caregivers Overcoming Real-Life Struggles to Inspire OthersEisai Inc. and METAvivor today announced the launch of Elements, a new initiative of the #ThisIsMBC campaign. Elements spotlights nine people living with metastatic breast cancer (MBC) and their...
-
Nov 27, 2018
Eisai announced today that new study results on its in-house discovered and developed anticancer agent eribulin mesylate (marketed as HALAVEN®) will be presented during the 41st San Antonio...
-
Nov 9, 2018First presentation of LENVIMA and KEYTRUDA combination data in patients with metastatic non-small cell lung cancer, metastatic melanoma and metastatic urothelial carcinoma from Study 111/KEYNOTE-146
Tokyo and Kenilworth, N.J., Nov. 9, 2018 – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today...
Oct 24, 2018Eisai Inc. announced today the presentation of four abstracts at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Washington, D.C. from November 9-11. The data to be...